X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (42) 42
life sciences & biomedicine (40) 40
humans (31) 31
female (18) 18
male (17) 17
phase-3 trial (17) 17
middle aged (15) 15
oncology (15) 15
aged (14) 14
adult (11) 11
open-label (11) 11
controlled phase-3 trial (10) 10
cancer (9) 9
double-blind (9) 9
phase-3 (9) 9
survival (9) 9
care and treatment (8) 8
clinical neurology (8) 8
neurosciences & neurology (8) 8
multiple sclerosis (7) 7
placebo-controlled phase-3 (7) 7
surgery (7) 7
treatment outcome (7) 7
aged, 80 and over (6) 6
chemotherapy (6) 6
patients (6) 6
abridged index medicus (5) 5
analysis (5) 5
clinical trials (5) 5
cohort studies (5) 5
immunotherapy (5) 5
medicine & public health (5) 5
randomized controlled-trial (5) 5
alvimopan (4) 4
chronic noncancer pain (4) 4
health aspects (4) 4
interferon (4) 4
ipilimumab (4) 4
lymphocytes t (4) 4
medical research (4) 4
multicenter (4) 4
multiple sclerosis, relapsing-remitting - drug therapy (4) 4
oral bg-12 (4) 4
pharmacology & pharmacy (4) 4
placebo-controlled trial (4) 4
studies (4) 4
survival rate (4) 4
transplantation (4) 4
usage (4) 4
young adult (4) 4
1st-line treatment (3) 3
adolescent (3) 3
alemtuzumab (3) 3
antibodies, monoclonal, humanized - therapeutic use (3) 3
cancer and oncology (3) 3
cancer och onkologi (3) 3
cetuximab (3) 3
dabrafenib (3) 3
disability evaluation (3) 3
drug therapy (3) 3
follow-up studies (3) 3
general & internal medicine (3) 3
health care sciences & services (3) 3
health economics (3) 3
immunologi inom det medicinska området (3) 3
immunologic factors - therapeutic use (3) 3
immunology (3) 3
immunology in the medical area (3) 3
interferon beta-1a (3) 3
lung neoplasms - drug therapy (3) 3
medicine, general & internal (3) 3
metastasis (3) 3
metastatic melanoma (3) 3
neurology (3) 3
peripheral blood (3) 3
prevalence (3) 3
prognosis (3) 3
prospective studies (3) 3
radiotherapy (3) 3
registries (3) 3
remission (3) 3
research (3) 3
review article (3) 3
risk factors (3) 3
safety (3) 3
survival analysis (3) 3
vemurafenib (3) 3
1st complete remission (2) 2
acid esters (2) 2
acute myeloid leukemia (2) 2
adenocarcinoma (2) 2
analgesics, opioid - adverse effects (2) 2
anesthesiology (2) 2
angiogenesis inhibitors - therapeutic use (2) 2
animals (2) 2
antibodies, monoclonal, humanized - adverse effects (2) 2
antineoplastic combined chemotherapy protocols - therapeutic use (2) 2
autoimmune (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Oncotarget, ISSN 1949-2553, 2017, Volume 8, Issue 44, pp. 76029 - 76043
.... This multicenter randomized phase-3 trial was aimed to test for superiority of chemosensitivity-directed combination chemotherapy compared to standard dacarbazine monochemotherapy, and to demonstrate... 
Chemosensitivity | Individualized chemotherapy | Melanoma | Phase-3 trial | Oncology | Life Sciences & Biomedicine | Science & Technology | Cell Biology
Journal Article
Lancet neurology, ISSN 1474-4422, 04/2017, Volume 16, Issue 4, pp. 271 - 281
Journal Article
The New England journal of medicine, ISSN 1533-4406, 03/2017, Volume 376, Issue 11, pp. 1027 - 1037
Journal Article
Neurology, ISSN 0028-3878, 09/2017, Volume 89, Issue 11, pp. 1117 - 1126
Journal Article
Journal Article
Diabetes & metabolism, ISSN 1262-3636, 11/2018, Volume 44, Issue 5, pp. 402 - 409
...) or insulin glargine 300 U/mL (Gla-300) versus glargine 100 U/mL (Gla-100) in trial-level meta-analyses of phase 3a clinical trials including people with type-2 diabetes. Methods... 
Trial-level meta-analyses | Insulin glargine 300 U/mL | Type-2 diabetes mellitus | Insulin degludec | Phase-3 clinical trials | Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology
Journal Article
Acta neurologica Scandinavica, ISSN 0001-6314, 01/2017, Volume 135, Issue 1, pp. 17 - 24
Journal Article
Journal Article